Saarikoski SV - Search Results

1

CD44 expression indicates favorable prognosis in epithelial ovarian cancer.

Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, Kosma VM. Sillanpää S, et al. Among authors: saarikoski sv. Clin Cancer Res. 2003 Nov 1;9(14):5318-24. Clin Cancer Res. 2003. PMID: 14614016

2

Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer.

Suhonen KA, Anttila MA, Sillanpää SM, Hämäläinen KM, Saarikoski SV, Juhola M, Kosma VM. Suhonen KA, et al. Among authors: saarikoski sv. Eur J Cancer. 2007 May;43(8):1300-7. doi: 10.1016/j.ejca.2007.03.007. Epub 2007 Apr 19. Eur J Cancer. 2007. PMID: 17448653

3

Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis.

Voutilainen K, Anttila M, Sillanpää S, Tammi R, Tammi M, Saarikoski S, Kosma VM. Voutilainen K, et al. Int J Cancer. 2003 Nov 10;107(3):359-64. doi: 10.1002/ijc.11423. Int J Cancer. 2003. PMID: 14506734 Free article.

4

Prognostic significance of iNOS in epithelial ovarian cancer.

Anttila MA, Voutilainen K, Merivalo S, Saarikoski S, Kosma VM. Anttila MA, et al. Gynecol Oncol. 2007 Apr;105(1):97-103. doi: 10.1016/j.ygyno.2006.10.049. Epub 2006 Dec 15. Gynecol Oncol. 2007. PMID: 17174383

5

Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer.

Anttila M, Kosma VM, Ji H, Wei-Ling X, Puolakka J, Juhola M, Saarikoski S, Syrjänen K. Anttila M, et al. J Clin Oncol. 1998 Aug;16(8):2591-600. doi: 10.1200/JCO.1998.16.8.2591. J Clin Oncol. 1998. PMID: 9704708

6

p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer.

Anttila MA, Kosma VM, Hongxiu J, Puolakka J, Juhola M, Saarikoski S, Syrjänen K. Anttila MA, et al. Br J Cancer. 1999 Apr;79(11-12):1870-8. doi: 10.1038/sj.bjc.6690298. Br J Cancer. 1999. PMID: 10206307 Free PMC article.

7

Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer.

Sillanpää S, Anttila M, Voutilainen K, Ropponen K, Turpeenniemi-Hujanen T, Puistola U, Tammi R, Tammi M, Sironen R, Saarikoski S, Kosma VM. Sillanpää S, et al. Gynecol Oncol. 2007 Feb;104(2):296-303. doi: 10.1016/j.ygyno.2006.09.004. Epub 2006 Oct 10. Gynecol Oncol. 2007. PMID: 17034838

8

Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer.

Sillanpää S, Anttila M, Suhonen K, Hämäläinen K, Turpeenniemi-Hujanen T, Puistola U, Tammi M, Sironen R, Saarikoski S, Kosma VM. Sillanpää S, et al. Tumour Biol. 2007;28(5):280-9. doi: 10.1159/000110426. Epub 2007 Oct 26. Tumour Biol. 2007. PMID: 17962725

9

Obstetric prognosis after placental abruption.

Toivonen S, Heinonen S, Anttila M, Kosma VM, Saarikoski S. Toivonen S, et al. Fetal Diagn Ther. 2004 Jul-Aug;19(4):336-41. doi: 10.1159/000077962. Fetal Diagn Ther. 2004. PMID: 15192293

10

Management of stage-I borderline ovarian tumors.

Ji H, Yliskoski M, Anttila M, Syrjänen K, Saarikoski S. Ji H, et al. Int J Gynaecol Obstet. 1996 Jul;54(1):37-44. doi: 10.1016/0020-7292(96)02674-4. Int J Gynaecol Obstet. 1996. PMID: 8842816

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241 results

Search Page